Find uplifting stories about heroes, innovations, and solutions
6770 results for "** ptsd treatment"
A groundbreaking trial shows military veterans experiencing dramatic improvements in PTSD symptoms after just one session with ibogaine, a powerful natural psychedelic. The research could open new doors for millions struggling with treatment-resistant trauma.
The FDA is accelerating approval for psilocybin and MDMA-like therapies to treat depression and PTSD, potentially opening new doors for millions struggling with mental health conditions. Three companies are now on an expedited path to bring these promising treatments to patients who haven't found relief from traditional options.
A groundbreaking study shows that adding robotic-guided magnetic brain stimulation to therapy dramatically reduced combat PTSD symptoms in 85% of military personnel and veterans. The treatment could help up to 500,000 service members suffering from this debilitating condition.
A breakthrough brain stimulation technique combined with therapy helped 85% of military personnel dramatically reduce PTSD symptoms in just 30 days. This precision treatment offers new hope for veterans who haven't found relief with traditional methods.
A revolutionary brain stimulation therapy helped 85% of combat veterans dramatically reduce PTSD symptoms when combined with psychotherapy. The breakthrough offers new hope for hundreds of thousands of service members still struggling years after deployment.
President Trump signed an executive order directing federal agencies to speed up approval of psychedelic therapies for PTSD, backed by $50 million in new research funding. The move could bring relief to millions of veterans and trauma survivors as soon as this summer.
A medication that helped Vietnam veterans overcome PTSD in just weeks could soon offer hope to Israeli soldiers struggling with trauma. After decades of research, psychiatrist Dr. Hillel Glover has patented nalmefene as a potential breakthrough treatment that addresses all PTSD symptoms.
The FDA is accelerating reviews of three psychedelic medications for depression and PTSD, moving promising mental health treatments closer to patients who desperately need them. Millions struggling with treatment-resistant conditions could soon have groundbreaking new options.
Scientists in Melbourne discovered a specific brain circuit that explains why common PTSD treatments work brilliantly for some patients but fall short for others. The breakthrough could help millions get therapy that actually matches their brain's needs.
Veterans with combat PTSD saw significant symptom reduction using MRI-guided brain stimulation in a clinical trial. This non-invasive treatment could offer new hope for those who haven't found relief with traditional therapy.
A presidential order is accelerating research on ibogaine, a plant-based treatment showing promise for veterans with PTSD and people battling depression. The FDA says approval could come within months instead of years.
A single treatment with ibogaine, a powerful plant-based compound, helped 30 special forces veterans significantly reduce their PTSD symptoms in a Stanford University study. The promising results offer new hope for military veterans struggling with trauma and mental health challenges.
The Department of Veterans Affairs is testing MDMA-assisted therapy to treat veterans struggling with both PTSD and alcohol addiction, marking a new chapter in mental health care. This trial joins 19 other VA studies exploring how psychedelic treatments could help those traditional methods haven't reached.
The FDA is accelerating breakthrough psychedelic therapies for treatment-resistant depression, PTSD, and alcohol use disorder after a presidential directive. Veterans and millions struggling with serious mental illness could gain access to promising new options backed by rigorous science.
President Trump signed an executive order to speed FDA review of psychedelic treatments showing 80-90% reduction in PTSD symptoms among veterans. The breakthrough therapy could help over 6,000 veterans who die by suicide each year.
President Trump signed an executive order to expand access to psychedelic therapies for conditions like PTSD, depression, and addiction. The move signals growing mainstream acceptance of treatments once considered fringe medicine.
A groundbreaking treatment that could prevent PTSD before it takes hold just cleared a major regulatory hurdle. The FDA has approved human trials for RST-101, a drug designed to stop trauma from becoming chronic psychological distress.
President Trump signed an executive order to accelerate research into psychedelic drugs for mental health treatment, directing $50 million to state programs. Veterans and advocacy groups hope the move could unlock new treatments for PTSD and depression.
Bipartisan legislation introduced by veteran senators would create a dedicated office to bring emerging mental health therapies, including psychedelics, to veterans struggling with PTSD and depression. The bill sets up infrastructure now so veterans can access innovative treatments the moment they receive FDA approval.
A new executive order accelerates research into psychedelic medicines for mental illness, prioritizing veterans facing treatment-resistant PTSD and depression. The move ends decades of federal prohibition and could offer hope to the 17 veterans who die by suicide every day.
Showing 20 of 6770